Categories
Change Password!
Reset Password!
Insomnia has affected 10-20% of adults globally.
Dimdazenil reduces sleep latency and increases sleep duration in insomnia patients, without causing daytime drowsiness or impairing function. It shows a strong safety profile with no significant rebound effects.
Insomnia has affected 10-20% of adults globally. Despite available treatments, gaps have remained in finding treatments that help in sleep maintenance and minimizing functional impairments. Hence, this study sought to investigate Dimdazenil's efficacy and safety for insomnia management.
An extensive search of randomized controlled trials was conducted, including both published and unpublished studies from inception to July 19, 2024. Due to the scarcity of studies, data were narratively synthesized.
Eventually, 4 trials were incorporated. Dimdazenil remarkably improved sleep latency and total sleep duration, without arousing excessive daytime tiredness or compromising daytime functionality. The safety and tolerability profile was generally acceptable, with no significant issues related to withdrawal, drug residues, or rebound effects.
In insomnia-affected individuals, Dimdazenil provided substantial improvements in sleep initiation and maintenance. It also demonstrated a good safety and tolerability profile, while maintaining daytime functionality. However, further research with larger sample sizes and longer follow-ups is needed to assess its long-term safety and efficacy.
Neurological Sciences
Dimdazenil for the treatment of insomnia: a systematic review and narrative synthesis
Shan Ran et al.
Comments (0)